Twist Bioscience Stock News

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick Weiss sold 2,801 shares of the businesss stock in a transaction on Tuesday, December 14th. The shares were sold at an average price of $84.00, for a total transaction of $235,284.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through []

Shares of Twist Bioscience Co. (NASDAQ:TWST) gapped up prior to trading on Thursday . The stock had previously closed at $84.16, but opened at $89.24. Twist Bioscience shares last traded at $88.96, with a volume of 1,959 shares. TWST has been the subject of several research reports. Robert W. Baird reduced their target price on []

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Sosei Group Corporation (the Company; TSE: 4565), the world leader in GPCR-focused structure-based drug design (SBDD) and development, announced a strategic collaboration to discover therapeutic antibodies against G protein-coupled receptors (GPCR) identified by Sosei Heptares. The

Environmental Impact Acquisition (NASDAQ:ENVI) and Twist Bioscience (NASDAQ:TWST) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations and institutional ownership. Earnings and Valuation This table compares Environmental Impact Acquisition and Twist Biosciences gross revenue, earnings []

Twist Bioscience Co. (NASDAQ:TWST) CFO James M. Thorburn sold 7,000 shares of the businesss stock in a transaction dated Wednesday, December 8th. The shares were sold at an average price of $89.37, for a total value of $625,590.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available []

Twist Bioscience Corporation (NASDAQ:TWST) price on Friday, December 10, rose 0.24% above its previous days close as an upside momentum from buyers pushed the stocks value to $83.10. A look at the stocks price movement, the close in the last trading session was $82.90, moving within a range at $82.50 and $86.81. The beta value Analysts Provide Insight Into Twist Bioscience Corporations (TWST) Potential. Read More »

Environmental Impact Acquisition (NASDAQ:ENVI) and Twist Bioscience (NASDAQ:TWST) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends. Earnings & Valuation This table compares Environmental Impact Acquisition and Twist Biosciences top-line revenue, earnings [] The post Environmental Impact Acquisition (NASDAQ:ENVI) & Twist Bioscience (NASDAQ:TWST) Head-To-Head Comparison appeared first on ETF Daily News .

Related Stocks: TWST ,

Sumitomo Mitsui Trust Holdings Inc. cut its stake in Twist Bioscience Co. (NASDAQ:TWST) by 15.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,146,110 shares of the companys stock after selling 381,800 shares during the period. Sumitomo Mitsui Trust Holdings []

Twist Bioscience Co. (NASDAQ:TWST) insider Patrick John Finn sold 1,758 shares of the companys stock in a transaction on Thursday, December 2nd. The stock was sold at an average price of $88.04, for a total value of $154,774.32. The transaction was disclosed in a document filed with the SEC, which can be accessed through the []

Twist Bioscience Corporation (NASDAQ:TWST) price closed higher on Tuesday, December 07, jumping 10.38% above its previous close. >> 7 Top Picks for the Post-Pandemic Economy > 7 Top Picks for the Post-Pandemic Economy

The stock price of Twist Bioscience Corp (NASDAQ: TWST) increased by 10.38% today. This is why it happened.

Analyst estimates suggest the stock market isn't giving these stocks the attention they deserve.

Twist Bioscience (NASDAQ:TWST) and Cidara Therapeutics (NASDAQ:CDTX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, institutional ownership and profitability. Profitability This table compares Twist Bioscience and Cidara Therapeutics net margins, return on equity and return []

Millennium Management LLC lowered its stake in shares of Twist Bioscience Co. (NASDAQ:TWST) by 53.0% in the second quarter, HoldingsChannel reports. The fund owned 18,589 shares of the companys stock after selling 20,993 shares during the quarter. Millennium Management LLCs holdings in Twist Bioscience were worth $2,477,000 at the end of the most recent quarter. []